Manager TitleAgeSince
Chief Executive Officer 52 01/04/2023
President 56 -
Chief Tech/Sci/R&D Officer - 02/03/2022
Director TitleAgeSince
Director/Board Member 69 01/02/2009
Director/Board Member 66 27/02/2015
Chairman 52 01/04/2023
Date Insider Type Main position Quantity % Market Cap.
27/04/23Issuer sale

Director

134,059 0.3195%
27/04/23Issuer sale

Director

22,853 0.0545%
27/04/23Issuer sale

Chief Financial Officer

173,008 0.4123%
Change 5-day change 1-year change 3-year change Capi.($)
+0.15%+0.10% - - 844M
+0.94%+6.46%-29.96%-12.68% 164B
+1.48%+2.07%-5.86%-7.08% 104B
-0.29%+5.26%-4.44%+51.57% 55.67B
-2.09%-6.13%+50.84%+54.81% 52.92B
+3.00%+8.29%-8.74%-39.62% 42.96B
+2.91%+8.15% - - 32.87B
+2.17%-3.22%-18.75%-43.21% 27.07B
+1.24%+6.98%+60.30%-5.01% 24.79B
+2.41%+6.45%-9.68%-0.53% 21.02B
Average +1.19%+3.42%+4.21%-0.22% 58.32B
Weighted average by Cap. +1.04%+3.85%-5.42%-0.10%
Logo Cardiovascular Systems, Inc.
Cardiovascular Systems, Inc. is a medical technology company. The Company is engaged in treating patients suffering from peripheral and coronary artery diseases, including those with arterial calcium. The Company has developed orbital atherectomy systems (OAS) for both peripheral and coronary clinical applications. The primary base of its business is catheter-based platforms capable of treating a range of vessel sizes and plaque types, including calcified plaque. Its peripheral artery disease (PAD) products are catheter-based platforms capable of treating a range of plaque types in leg arteries both above and below the knee, including calcified plaque. Its coronary artery disease (CAD) product, the Diamondback 360 Coronary OAS (Coronary OAS), is a catheter-based platform designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to de novo, severely calcified coronary artery lesions.
Employees
725
  1. Stock Market
  2. Stocks
  3. CSII Stock